18 May 2013
Keywords: novartis, drug, shows, strong, data, sjia/caps, swiss
Article | 03 November 2008
Swiss drug major Novartis has presented Phase III data demonstrating that ACZ885 (canakinumab) achieved clinical remission after just one
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 November 2008
17 May 2013
© 2013 thepharmaletter.com